Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-25T17:28:55.492Z Has data issue: false hasContentIssue false
  • English
  • Français

Blood tests for patients prescribed psychotropics: what, when and why?

Published online by Cambridge University Press:  02 January 2018

Carol Paton  and
Dominic Beer
Dominic Beer
Affiliation:
Bexley Hospital Bexley, Kent DA5 2BW
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Although baseline blood tests are routinely checked on hospital admission when patients may be medication-free, it is frequently forgotten that psychotropic drugs can cause a wide range of abnormalities in such tests, some common and some very rare. These abnormalities, and the monitoring requirements associated with them are summarised in Table 1.

Type
Drug Information Quarterly
Information
Psychiatric Bulletin , Volume 20 , Issue 6 , June 1996 , pp. 356 - 358
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Royal College of Psychiatrists, 1996

References

1 Clozaril Newsletter (1995) Update on neutropenia. Clozaril Newsletter, 12.Google Scholar
2 Largactil Data Sheet (1996–96) ABPI Data Sheet Compendium 1995–96. London: Datapharm Publications Ltd, pp. 1386–1388.Google Scholar
3 Regal, R., Billi, J. E. & Glazer, H. M. (1987) Phenothiazine induced cholestatic jaundice. Clinical Pharmacy, 6, 787–794.Google Scholar
4 Castillo, E., Rubin, R. & Holsboer-Trachsler, E. (1989) Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. American Journal of Psychiatry, 146, 324–328.Google ScholarPubMed
5 Committee on Safety of Medicines (1989) Mianserin and white blood cell disorders In the elderly. Current Problems, 25.Google Scholar
6 Committee on Safety of Medicines (1994a) L-tryptophan (Optimax): limited availability for resistant depression. Current Problems In Pharmacovigilance, 20, 2.Google Scholar
7 Committee on Safety of Medicines (1994b) Antidepressant-induced hyponatraemia. Current Problems in Pharmacovigilance, 20, 6–6.Google Scholar
8 Aronson, J. K. & Reynolds, D. J. M. (1992) ABC of monitoring drug therapy: lithium. British Medical Journal, 305, 1273–1276.CrossRefGoogle ScholarPubMed
9 Tohen, M., Castillo, J., Baldessarini, R., et al (1996) Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2228 patients at risk. American Journal of Psychiatry. 152, 413–418.Google Scholar
10 Yassa, R., Iskandar, H., Nastase, C., et al (1988) Carbamazepine and hyponatremia in patients with affective disorder. American Journal of Psychiatry, 145, 339–442.Google ScholarPubMed
11 Tegretol Data Sheet (1996–96) ABPI Data Sheet Compendium 1996–96. London: Datapharm Publications Ltd, pp. 614–619.Google Scholar
12 Paton, C. & Procter, A. W. (1993) Carbamazepine monitoring. Psychiatric Bulletin, 17, 718–720.CrossRefGoogle Scholar
13 Epilim Data Sheet (1996–96) ABPI Data Sheet Compendium 1996–96. London: Datapharm Publications Ltd, pp. 1669–1661.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.